Alex Gorsky, the CEO whose nine-year tenure at J&J was marred by law­suits over the com­pa­ny’s talc ba­by pow­der and opi­oids, will ...

→ An­oth­er cut of pos­i­tive in­ter­im da­ta have lift­ed ex­pec­ta­tions that Ad­verum’s gene ther­a­py that could give the an­ti-VEGF de­vel­op­ers … ...

In the midst of their $500 mil­lion pro­gram to build a Covid-19 vac­cine with BioN­Tech, Pfiz­er has an­nounced a siz­able deal to com­mer­cial­ize a … ...

The fed­er­al gov­ern­ment has on­ly sent four ship­ments of Mer­ck’s Covid-19 an­tivi­ral mol­nupi­ravir (about 400,000 cours­es in each ship­ment) na­tion­wide, and al­ready HHS is re­port­ing … ...

With the pan­dem­ic po­ten­tial­ly en­ter­ing its lat­er stages, ma­jor drug­mak­ers like Mer­ck have jumped in to aid in the gar­gan­tu­an task of man­u­fac­tur­ing oth­er … ...

The Fed­er­al Trade Com­mis­sion wants more in­for­ma­tion on Pfiz­er’s takeover of Seagen be­fore it will make a rul­ing on whether it will clear the … ...

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to … ...

PARIS — Last fall De­ci­phera suf­fered through a dis­as­trous set­back $DCPH with its lead drug, Qin­lock, which had been ap­proved as a fourth-line ther ...

Weeks away from a po­ten­tial EUA ap­pli­ca­tion, Mod­er­na an­nounced they have com­plet­ed en­roll­ment in their 30,000-per­son Phase III Covid-19 vac­cine tri­al, with over a … ...

Af­ter Pfiz­er and BioN­Tech scored the FDA’s emer­gency use au­tho­riza­tion for their mR­NA-based Covid-19 shot late last week, hopes are high that one or … ...

A bill that re­quires the Di­rec­tor of Na­tion­al In­tel­li­gence to de­clas­si­fy new in­for­ma­tion on the ori­gins of Covid-19 passed the House … ...

→ A long­time re­searcher in car­diac re­gen­er­a­tive med­i­cine has closed a $26 mil­lion Se­ries B to ad­vance his de­vel­op­ment of iP­SC-de­rived car­diomy­ocytes as a treat­ment … ...